semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 0.083-2.917,  Pneumonia Age 1-35 months Admitting diagnosis is pneumonia or lower respiratory tract illness/infection Written informed consent obtained from parent or legally authorized representative  Discharged as an case in the last 90 days Age 1-35 months with no systemic illness (mild respiratory illness is not an criteria) Written informed consent obtained from parent or legally authorized representative Known underlying serious disease (e.g., congenital heart diseases, immunodeficiency disorders, sickle cell anemia etc.) which may negatively influence the participant's ability to participate in the study Currently enrolled into the study
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  MUSCULAR AQUIRED WEAKNESS Bioelectrical Impedance Analysis Muscular Ultrasound All patients aged 18 or older and with a recent (<48h) ICU entry requiring mechanical ventilation for at least 3 days will be considered for enrolment  not intubated patients patients with an ICU prevision of stay less than 3 days
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Total Knee Arthroplasty Adults who have OA and need a total knee replacement  Patients had abnormal blood coagulation. 2. Patients were diagnosed as rheumatoid arthritis, traumatic osteoarthritis, ankylosing, spondylitis, hemophilic arthritis, peripheral vascular disease. 3. Cold urticaria. 4. Preoperative anticoagulation, patients had preoperative deep vein thrombosis (DVT). 5. Preoperative history of anemia
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 19.0-65.0,  Electrical Cardiometry Transthoracic Echocardiography Fluid Responsiveness Sepsis Stoke Volume Age from 19 to 65 years old Clinical of sepsis [acute change in sepsis-related organ failure assessment (SOFA) variables ≥ 2 points consequent to the infection which PaO2/FiO2 ratio < 300, Glasgow Coma Scale score < 15, mean arterial pressure (MAP) < 70 mmHg, serum creatinine >1.2 mg/dl or urine output < 0.5 ml/kg/h, serum bilirubin > 1.2 mg/dL, platelet count < 150 X 103 /µl] Developing hypotension (mean arterial blood pressure ≤ 65 mmHg)  Other causes of shock Previous cardiac disease Rhythm other than sinus rhythm or heart rate > 140 beats/min Chronic renal failure
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Kidney Disease Requiring Chronic Dialysis Hemodialysis, Home Electric Impedance Patient with chronic end stage renal failure Patient prevalent in home daily hemodialysis with low dialysate rate for more than 3 months Patient followed at the University Hospital of Caen, Tenon Hospital (Paris), CHG Saint-Lô, CHG Alençon, CHG Flers, CHG Lisieux, CHG Evreux, Rouen, CH Le Havre, A.U.B Rennes, A.D.P.C. Marseille  Reversindication to impedancemetry: patient with a pacemaker or an implantable defibrillator Population not validated for impedancemetry: pregnant or lactating woman, major amputation
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-40.0,  Healthy Men and Women Healthy men and women aged 18-40 years old 2. Subjects are willing to maintain their normal eating/drinking habits and exercise habits to avoid changes in body. weight over the duration of the study. 3. Are able to understand the nature of the study. 4. Able to give signed written informed consent. 5. Signed informed consent form  Medical history of cardiovascular disease including coronary artery disease, cerebrovascular disease and peripheral artery disease. 2. Hypertensive, as defined as SBP superior or equal to 140 mmHg. 3. Obese participants, defined as BMI superior or equal to 30. 4. Medical history of diabetes mellitus, metabolic syndrome, terminal renal failure or malignancies. 5. Abnormal heart rhythm (lower or higher than 60-100 bpm). 6. Allergies to berries or other significant food allergy. 7. Subjects under medication that can affect the cardiovascular system or on vitamin/dietary supplements. 8. Subjects who have lost more than 10% of their weight in the past 6 months or are currently in a diet 9. Subjects who reported participant in another study within one month before the study start. 10. Subjects who smoke an irregular amount of cigarettes per day. 11. pregnant women or planning to become pregnant in the next 6 months. 12. Any reason or condition that in the judgment of the clinical investigator(s) may put the subject at unacceptable risk or that may preclude the subject from understanding or complying with the study's requirements
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 0.25-999.0,  Autoimmune Hemolytic Anemia Sufficient comprehension of the Dutch language Signed informed consent by patient and/or parent/caretaker or donor Patients older than 3 months Patients with a positive DAT, a positive eluate and signs of hemolysis* Patients with a positive DAT with complement only, negative eluate, but with signs of hemolysis Donors with a (repeatedly) positive DAT and a positive eluate and/or clinically relevant cold auto-antibodies  Prior in the study
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Septicemia in Hemodialysis patients over 18 year old suspicion of septicemia in hemodialysis patient with catheter patient oral consent prior to in the study  patients who went through the A&E department patients who have received an antimicrobial therapy more than 8 hours long patient under legal protection
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Infection Abdominal years or older undergone midline laparotomy and managed with an open abdomen for at least one day contaminated or dirty wound classification  Less than 18 years of age Prisoners Pregnant females Non-surgical patients
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 15.0-999.0,  HIV Infections Immune Activation Comorbidities Consenting pregnant woman of Bantu origin of ≥15 years of age, at least 20 weeks of gestation at enrolment and planning to deliver at any of the 4 study sites, Kuwadzana, Rujeko, Glenview or Budiriro. Mothers should be willing to be followed together with their babies from delivery, and willing to provide the required data and biological specimens in follow-up visits for two years  Presence of severe maternal mental disorders
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Locally Advanced Cancer Metastatic Cancer Chronic Respiratory Failure Chronic Heart Failure Chronic Liver Failure Chronic Renal Failure Patients admitted to Molinette Hospital (A.O.U. "Città della Salute e della Scienza"), affected by locally advanced/metastatic cancer not suitable to antineoplastic therapy locally advanced/metastatic cancer suitable for palliative antineoplastic therapy locally advanced/metastatic cancer with uncontrolled symptoms end-stage heart failure end-stage respiratory failure end-stage liver failure end-stage renal failure  not able to be administered the screening tool major psychiatric disorders informed consent refusal
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hypotension Hemodynamic Instability Renal Failure Myocardial Injury Anesthesia Patients undergoing lung surgery with one-lung-ventilation General anesthesia Age ≥ 18 years  Participation in another (interventional) study Pregnancy and nursing mothers Surgery without controlled ventilation ASA I or IV Contraindication for invasive blood pressure monitoring Coagulation disorder Arterial Fibrillation
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Sepsis Infective Endocarditis Pneumonia, Bacterial community-acquired pneumonia, severe course (according to IDSA / ATs criteria) and / or sepsis with different localization of the primary focus (SOFA> 2) the patient's ability to comply with the instructions of the research doctor and follow the procedures required by the test protocol informed consent  acute and chronic heart failure renal failure acute and chronic liver failure taking medications of the statin group during the last month before the study diabetes in the stage of clinical and metabolic decompensation acute and chronic leukemia, severe anemia pregnancy or lactation HIV infection drug addiction immunosuppressive therapy
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 17.0-70.0,  Fabry Disease Gaucher Disease Niemann-Pick Disease, Type C Lysosomal Storage Diseases All consenting patients with a prior diagnosis of FD, GD or NPC will be included in the study. Control participants will be healthy volunteers  Patients who are unable to provide consent or to perform a blood or urine test will be excluded
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 0.5-45.0,  Typhoid Healthy participants 6 months to 45 years of age at enrollment 2. Participants/Parent(s)/LAR who have voluntarily given informed consent/assent 3. Participants/Parent(s)/LAR willing to follow the study procedures of the study and available for the entire duration of the study  Child with a congenital abnormality 2. Participant who has already received meningococcal conjugate vaccine 3. Participants concomitantly enrolled or scheduled to be enrolled in another trial 4. Known history of immune function disorders including immunodeficiency diseases (Known HIV infection or other immune function disorders) 5. Chronic use of systemic steroids (>2 mg/kg/day or >20 mg/day prednisone equivalent for periods exceeding 10 days), cytotoxic or other immunosuppressive drugs 6. Receipt of blood or blood-derived products in the past 3 months 7. Participant with a previously ascertained or suspected disease caused by S. Typhi (confirmed either clinically, serologically or microbiologically) 8. Participant who has had household contact with and/or intimate exposure to an individual with laboratory-confirmed S. Typhi 9. Individual who has previously received a typhoid vaccine 10. Participant who has received other vaccines from 1 month prior to test vaccination or planned to receive any vaccine within 1 month (except a measles containing vaccine as per government vaccination campaign) 11. Known history or allergy to vaccines or other medications 12. History of uncontrolled coagulopathy or blood disorders 13. Any abnormality or chronic disease which in the opinion of the investigator might be detrimental for the safety of the participant and interfere with the assessment of the study objectives 14. Any female participant who is lactating, pregnant* or planning for pregnancy during the course of study period 15. Participants/Parent(s)/LAR planning to move from the study area before the end of study period 16. As per Investigator's medical judgement individual could be excluded from the study in spite of meeting all inclusion/ mentioned above
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Helminthiasis Helminth Infection The included volunteer is a researcher within parasitology with focus on Trichuris trichiura and Trichiura suis. He planned to infect himself under medical supervision. This was his third self-infection with Trichuris. The only clinical criterion for his in the study was that he was healthy  N/A
Patient description: The patient is a 23-year-old man who came to the hospital with high blood pressure (175/95 mmHg) and signs of septicemia. He developed respiratory failure requiring mechanical ventilation and renal failure requiring hemodialysis. His blood smear showed microangiopathic hemolytic anemia and thrombocytopenia. His blood tests revealed elevated lactate dehydrogenase and reduced human complement C3 levels with a normal coagulation profile. He was diagnosed with atypical hemolytic uremic syndrome. He was treated with plasma exchange and corticosteroids. He has been previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine. The genetic survey revealed ADAMTS13 >10%.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Irritable Bowel Syndrome Patients who fulfil Rome IV for the diagnosis of IBS. 2. Patients were investigated to other gastrointestinal organic cause(s). 3. Moderate-to-severe IBS symptoms, as indicated by a score of ≥175 on the IBS Severity Scoring System (IBS-SSS)  Pregnant or lactating women. 2. The use of antibiotics or probiotics within 1 month prior to FMT. 3. Immunocompromised patients defined as those treated by immune suppressive medications. 4. Patients with co-morbidity such as kidney failure or chronic heart disease. 5. System disease such as diabetes. 6. Patients with serious psychiatric disorders or drug abuse